APR 26, 2018 08:00 AM PDT

Pre-clinical T cell immunotherapy strategies for overcoming immunosuppression in solid tumors

SPONSORED BY: Thermo Fisher Scientific - Applied Biosystems
5 36 4206

  • Postdoctoral Research Fellow, University of Washington and Fred Hutchinson Cancer Research Center
      Dr. Kristin G. Anderson is a Senior Postdoctoral Research Fellow in the Clinical Research Division of the Fred Hutchinson Cancer Research Center and in the Immunology Department of the University of Washington in Seattle, WA. Her research investigates strategies for treating solid tumors with adoptive T cell therapy. Currently, she is developing molecular engineering strategies to improve tumor eradication with genetically engineered cells in ovarian cancer, with the ultimate goal of translating her findings into treatment protocols for patients. Her team uses cutting-edge technologies, including deep transcriptome profiling and single cell RNA sequencing, to elucidate the molecular mechanisms driving T cell dysfunction in ovarian cancer. Using mouse models of cancer that recapitulate the hallmark immunosuppressive mechanisms in human disease, she is exploring strategies that improve the migration, persistence and function of genetically engineered T cells within solid tumors. While her findings are intended to inform the development of new immunotherapies for treating ovarian cancer patients, the mechanisms under investigation are operative in many solid tumors and her advances will likely have applicability to many other malignancies.


    DATE: April 26, 2018
    TIME: 08:00am PDT, 11:00am EDT, 5:00pm CEST

    Engineered T cells expressing a tumor antigen-specific receptor have revolutionized the field of cancer therapy for blood cancers. However, similar success has not generally been obtainable in solid tumors, in which the tumor microenvironment (TME) exhibits immunosuppressive effects against injected therapeutic T cells. Our studies have utilized mouse models demonstrated to recapitulate the immunosuppressive features of human cancers to test novel immunotherapy strategies, either alone or in combination. Strategies that incapacitate specific immune-inhibitory pathways operative in the TME can enhance T cell function and improve anti-tumor efficacy. Our results suggest such efforts will soon lead to translation of effective immunotherapies for human solid tumors.

    In this webinar, the speaker will:

    • Explain how analysis, including by transcriptome profiling, of appropriate immunocompetent models and human tissues can be used to predict obstacles to therapeutic human T cell function

    • Describe strategies for overcoming immunosuppressive TME features

    • Provide examples in ovarian and pancreatic cancer models of novel T cell engineering that improves the efficacy of adoptive T cell therapy


    For Research Use Only. Not for use in diagnostic procedures.

    Show Resources
    Loading Comments...